An Update on the Safety and Tolerability of Pimecrolimus Cream 1%: Evidence from Clinical Trials and Post-Marketing Surveillance

Publisher： Karger

E-ISSN： 1421-9832|215|1|27-44

ISSN： 1018-8665

Source： Dermatology, Vol.215, Iss.1, 2007-12, pp. : 27-44

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Management of Atopic Eczema with Pimecrolimus Cream 1% (Elidel®) in Paediatric Patients

By  

Dermatology, Vol. 215, Iss. 1, 2007-12 ,pp. : 3-17

Karger

Access to resources Recommend Favorite

Long-Term Efficacy and Safety of Pimecrolimus Cream 1% in Adults with Moderate Atopic Dermatitis

By  

Dermatology, Vol. 208, Iss. 4, 2004-06 ,pp. : 365-372

Karger

Access to resources Recommend Favorite

Efficacy and Safety of Pimecrolimus Cream 1% in Mild-to-Moderate Chronic Hand Dermatitis: A Randomized, Double-Blind Trial

By  

Dermatology, Vol. 221, Iss. 1, 2010-06 ,pp. : 71-77

Karger

Access to resources Recommend Favorite

Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial

By  

Dermatology, Vol. 222, Iss. 1, 2010-12 ,pp. : 36-48

Karger

Access to resources Recommend Favorite

The Role of Pimecrolimus Cream 1% (Elidel®) in Managing Adult Atopic Eczema

By  

Dermatology, Vol. 215, Iss. 1, 2007-12 ,pp. : 18-26

Karger

Access to resources Recommend Favorite